Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...

AbbVie is a Dividend King that's quickly moving past reliance on Humira. Enbridge shouldn't be affected by potential Canadian ...

Florida's Medicaid Fraud Control Unit secured the win through a multistate action. "Actions, like those alleged here, must be ...

The kickbacks were meant to encourage doctors to prescribe the migraine drug Nurtec ODT, which is a violation of the False Claims Act, the U.S. Department of Justice said. In October 2022, Pfizer ...

Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement ...

Pfizer Settles Its Subsidiary’s Kickback Allegations for Nearly $60 Million - Pfizer Inc. agreed to pay over $59,746,277 to ...

The Michigan Attorney General’s Office says the state has joined 37 other states and the territory of Puerto Rico in the ...

Pfizer posted Q4 revenue of $17.76 billion, up 22% YoY, with strong sales from Paxlovid, Vyndaqel, and Eliquis. The company reaffirmed its 2025 revenue outlook.

Pfizer expects to sufficiently de-lever its balance sheet ... loss of patent-based exclusivity and generic competition in certain international markets; Nurtec ODT/Vydura globally, up 39% ...

Pfizer Inc. (NYSE:PFE – Get Free Report) shares traded up 2.9% on Wednesday following a stronger than expected earnings ...

So were other acquired drugs, especially Nurtec ODT. Pfizer's cost-cutting efforts also paid off, with adjusted diluted earnings per share soaring more than 6x. Sure, Pfizer still faces patent ...